Ocusoft, Inc. Report issue

For profit Phase 4
Founded: Rosenberg TX United States (1986)
Status: No NME R&D (1986)

Organization Overview

First Clinical Trial
2014
NCT02139033
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

retaine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 4)

Keratoconjunctivitis (Phase 4)

Keratoconjunctivitis Sicca (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1